A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg

Sponsor
Dong-A ST Co., Ltd.
Study ID
NCT04653779
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Multi-center, open-label, single arm study to Evaluate the preference regarding convenience of medication, efficacy and safety of Sugamet XR tab. 5/1000mg in patients with Type 2 diabetes and renal diseases

Key Dates

First listed
Dec 4, 2020
Start date
Dec 31, 2020
Status verified
Dec 2020
Primary completion
May 31, 2021
Completion
Jul 31, 2021

Study Design

Enrollment
54 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Group A
    Patients receive Evogliptin 5mg/Metformin 1000mg once a day

Primary Outcome Measure

The preference regarding convenience of medication [ Time Frame: 12 weeks ]

Central Contacts

Related Studies